May 9 |
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
|
May 8 |
Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
|
May 8 |
Veru GAAP EPS of -$0.07 misses by $0.01, revenue of $4.14M
|
May 8 |
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
|
May 7 |
Veru Q2 2024 Earnings Preview
|
May 6 |
Critical Insights From Veru Analyst Ratings: What You Need To Know
|
May 2 |
Veru to Present at the GLP-1 Based Therapeutics Summit
|
May 1 |
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
|
Apr 30 |
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
|
Apr 30 |
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
|